While Biocon has this covered internally, for everyone else, the real headache right now is securing high-purity Semaglutide API and its intermediates
Inhouse product Semaglo 0.25 mg Injection contains Semaglutide , a glucagon-like peptide-1 (GLP-1) receptor agonist used for the management of type 2 diabetes mellitus (T2DM)
In addition to the gut, GLP-1 is produced within the brain, specifically in neurons located in the nucleus of the solitary tract (NTS)
This meant that the visceral discomfort due to UC was significantly reduced in the Si-DSS group compared with that in the Con-DSS group
van Dalfsen JH, Markus CR
If youre on the pill, your provider will usually recommend switching to a non-oral method, or adding a barrier method, for 4 weeks after you start and 4 weeks after each dose increase